In the last ten years developments in treatment of metastatic renal cell cancer (mRCC) provided unprecedented improvement in prognosis of this disease. In this review, treatment agents used in the treatment of mRCC were discussed by mechanisms of action. This review will provide an updated review of currently approved treatment options and newly studied agents will be mentioned. Finally current treatment choices are summarized.
Keywords: Renal cell carcinoma, immunotherapy, tyrosine kinase inhibitör, VEGF, mTORq